Gary Guthart knows a little something about disruptive innovation.
Intuitive Surgical
Intuitive Surgical CEO Gary Guthart on building a disruptive technology company (Page 2)
MassDevice: Is Intuitive a health care company or a robotics company?
Gary Guthart: I think we’re a high-tech, minimally invasive surgery company. We live at the intersection of high-tech and surgery. We’re not a diversified health care conglomerate – we don’t see ourselves getting into vaccines. I think where we can bring value is how we look at where surgery wants to go.
Device tax spurs Hill-Rom to lay off 200 | Wall Street Beat
Hill-Rom Holdings (NYSE:HRC) said it will lay off about 3% of its workforce, or roughly 200 workers, as it maneuvers to confront the medical device tax set to go into effect next year.
Report: Medtronic to shutter Ventor’s Israeli shop | Wall Street Beat
Medtronic (NYSE:MDT) is shutting down heart valve maker Ventor Technologies, which it acquired in 2009, and moving its R&D efforts to other site, according to an Israeli business journal.
Netanya, Israel-based Ventor is developing an aortic replacement valve called the Engager. Medtronic bought the company for $325 million 3 years ago.
Will Intuitive Surgical’s stock ever stop? | Wall Street Beat
Shares of Intuitive Surgical (NSDQ:ISRG) hit an all-time high yesterday of $529.70 and beat it today, as investors sent the shares to $531.35 apiece this morning.
The spikes followed an upgrade by analysts at Lazard Capital, who raised their price target on the stock to $575 from $525 and reinforced their “buy” rating.
VCs press Senate on “IPO On Ramp” bill | Wall Street Beat
The National Venture Capital Assn. is spearheading a drive to get a bill through the U.S. Senate that would make it easier for small companies to raise money by going public.
The "IPO On Ramp" measure would ease the regulatory requirements for IPOs and temporarily reduce the reporting burdens imposed by the Sarbanes-Oxley Act.
Edwards to re-state financials | Wall Street Beat
Edwards Lifesciences (NYSE:EW) said it will re-state its financial results for the first 3 quarters of 2011, “due to certain technical errors in the balance sheets and cash flow statements for these interim periods.”
The Irvine, Calif.-based heart valve maker said the errors involve the mis-statement of short-term investments as cash & equivalents, plus the way it treated tax benefits from stock plans.
Standard & Poor’s downgrades Medtronic | Wall Street Beat
Standard & Poor’s Ratings Services downgraded Medtronic’s (NYSE:MDT) credit rating after the company reported declines for its bread-and-butter CRM and spine businesses – which together accounted for more than 50 percent of its total Q2 revenues.
CRDM revenues were up 1.6 percent to $1.27 billion for the quarter, but defibrillator sales slid 5.0 percent to $708 million.
Moody’s raises Boston Scientific rating again | Wall Street Beat
St. Jude lands FDA win for 2 next-gen cardiac ablation catheters | Regulatory Roundup
St. Jude Medical Inc. (NYSE:STJ) won pre-market approval for 2 next-generation cardiac ablation systems this month, the Therapy Cool Path Duo and Safire Blu Duo catheters.
Both ablation systems use radiofrequency energy to freeze small areas of faulty cardiac tissue in patients with typical trial flutter, a type of arrhythmia in which patients experience abnormal heart rhythms or an abnormally fast heartbeat in the upper chambers of the heart.
Boston Scientific to hit the acquisitions trail | Wall Street Beat
Boston Scientific (NYSE:BSX) plans to hoard most of the more than $1 billion in free cash flow it expects to generate this year so it can make acquisitions to boost its top line, CFO Jeff Capello told analysts last week.